[go: up one dir, main page]

BR9814698A - Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase - Google Patents

Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase

Info

Publication number
BR9814698A
BR9814698A BR9814698-0A BR9814698A BR9814698A BR 9814698 A BR9814698 A BR 9814698A BR 9814698 A BR9814698 A BR 9814698A BR 9814698 A BR9814698 A BR 9814698A
Authority
BR
Brazil
Prior art keywords
inhibitor
combination
aldose reductase
glycogen phosphorylase
glycogen
Prior art date
Application number
BR9814698-0A
Other languages
English (en)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9814698A publication Critical patent/BR9814698A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Noise Elimination (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Superheterodyne Receivers (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO DE UM INIBIDOR DA ALDOSE-REDUTASE COM UM INIBIDOR DO GLICOGêNIO-FOSFORILASE"<D>. Composições e métodos de combinações farmacêuticas incluindo inibidores de aldose-redutase e inibidores de glicogênio-fosforilase. As composições e métodos são úteis para o tratamento de condições de resistência à insulina, tais como diabetes e na redução de lesão dos tecidos devida a isquemia.
BR9814698-0A 1997-11-21 1998-11-02 Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase BR9814698A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
BR9814698A true BR9814698A (pt) 2000-10-03

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814698-0A BR9814698A (pt) 1997-11-21 1998-11-02 Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase

Country Status (38)

Country Link
EP (1) EP1032424B9 (pt)
JP (1) JP2002504478A (pt)
KR (2) KR20010032304A (pt)
CN (1) CN1279617A (pt)
AP (1) AP911A (pt)
AR (1) AR016423A1 (pt)
AT (1) ATE205403T1 (pt)
AU (1) AU733304B2 (pt)
BG (1) BG104435A (pt)
BR (1) BR9814698A (pt)
CA (1) CA2310069A1 (pt)
DE (1) DE69801680T2 (pt)
DK (1) DK1032424T3 (pt)
DZ (1) DZ2656A1 (pt)
EA (1) EA002365B1 (pt)
ES (1) ES2161548T3 (pt)
GR (1) GR3037071T3 (pt)
GT (1) GT199800166A (pt)
HR (1) HRP20000327A2 (pt)
HU (1) HUP0100272A3 (pt)
ID (1) ID24524A (pt)
IL (1) IL135713A0 (pt)
IS (1) IS5453A (pt)
MA (1) MA26568A1 (pt)
NO (1) NO20002164L (pt)
OA (1) OA11379A (pt)
PA (1) PA8462301A1 (pt)
PE (1) PE135399A1 (pt)
PL (1) PL340643A1 (pt)
PT (1) PT1032424E (pt)
SK (1) SK7222000A3 (pt)
TN (1) TNSN98211A1 (pt)
TR (1) TR200001451T2 (pt)
UA (1) UA57811C2 (pt)
UY (1) UY25258A1 (pt)
WO (1) WO1999026659A1 (pt)
YU (1) YU30700A (pt)
ZA (1) ZA9810636B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2535700A (en) * 1999-02-12 2000-08-29 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
EP1741445B1 (en) 2000-01-21 2013-08-14 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005047297A1 (en) 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7786163B2 (en) 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EA015735B1 (ru) 2005-09-14 2011-10-31 Такеда Фармасьютикал Компани Лимитед Фармацевтические композиции на основе 2-[[6-[(3r)-3-амино-1-пиперидинил]-3,4-дигидро-3-метил-2,4-диоксо-1(2н)-пиримидинил]метил]бензонитрила
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
US8093257B2 (en) 2007-05-04 2012-01-10 Bristol-Myers Squibb Company [6,5]-bicyclic GPR119 G protein-coupled receptor agonists
AR067568A1 (es) 2007-07-17 2009-10-14 Bristol Myers Squibb Co Agonistas de receptor acoplado a proteina g gpr119 de piridona y una composicion farmaceutica que los contiene
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
CN102933576A (zh) 2010-04-08 2013-02-13 百时美施贵宝公司 作为gpr119调节剂的嘧啶基哌啶基氧基吡啶酮类似物
JP2013523894A (ja) 2010-04-14 2013-06-17 ブリストル−マイヤーズ スクイブ カンパニー 新規グルコキナーゼアクチベーターおよびその使用方法
BR112012028445A2 (pt) 2010-05-06 2016-07-19 Bristol Myers Squibb Co compostos de heteroarila bicíclica como moduladores de gpr119
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
DK2665477T3 (en) 2011-01-20 2015-12-14 Bionevia Pharmaceuticals Inc MODIFIED RELEASE COMPOSITIONS OF EPAL REST OR A DERIVATIVE THEREOF AND PROCEDURES FOR USING THE SAME
EP2850073B1 (en) 2012-05-16 2017-07-19 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
US9580422B2 (en) 2013-10-22 2017-02-28 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP3487862A1 (en) 2016-07-22 2019-05-29 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
EP0343273B1 (de) * 1988-05-27 1994-04-27 Deutsche ITT Industries GmbH Korrekturschaltung für ein digitales Quadratur-Signalpaar
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
AP624A (en) * 1995-06-06 1997-12-19 Pfizer Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
CA2342471C (en) * 1995-06-06 2002-10-29 Judith L. Treadway Heterocyclecarbonylmethyl amine intermediates

Also Published As

Publication number Publication date
IS5453A (is) 2000-04-14
JP2002504478A (ja) 2002-02-12
GR3037071T3 (en) 2002-01-31
AU733304B2 (en) 2001-05-10
UA57811C2 (uk) 2003-07-15
ZA9810636B (en) 2000-05-22
DZ2656A1 (fr) 2003-03-22
DK1032424T3 (da) 2001-11-19
DE69801680D1 (de) 2001-10-18
SK7222000A3 (en) 2001-09-11
UY25258A1 (es) 2000-12-29
KR20010032300A (ko) 2001-04-16
OA11379A (en) 2004-01-28
EP1032424B1 (en) 2001-09-12
NO20002164D0 (no) 2000-04-27
TNSN98211A1 (fr) 2005-03-15
ES2161548T3 (es) 2001-12-01
HRP20000327A2 (en) 2001-02-28
PT1032424E (pt) 2001-12-28
BG104435A (bg) 2001-01-31
HUP0100272A2 (hu) 2001-06-28
HUP0100272A3 (en) 2002-11-28
AP911A (en) 2000-12-07
PE135399A1 (es) 2000-01-15
EP1032424B9 (en) 2004-10-06
WO1999026659A1 (en) 1999-06-03
EP1032424A1 (en) 2000-09-06
DE69801680T2 (de) 2002-02-07
ID24524A (id) 2000-07-20
NO20002164L (no) 2000-07-19
PL340643A1 (en) 2001-02-12
CN1279617A (zh) 2001-01-10
TR200001451T2 (tr) 2002-06-21
PA8462301A1 (es) 2000-05-24
KR100661214B1 (ko) 2006-12-26
ATE205403T1 (de) 2001-09-15
IL135713A0 (en) 2001-05-20
AP9801401A0 (en) 1998-12-31
AU9555898A (en) 1999-06-15
CA2310069A1 (en) 1999-06-03
GT199800166A (es) 2000-04-19
MA26568A1 (fr) 2004-12-20
YU30700A (sh) 2002-12-10
EA002365B1 (ru) 2002-04-25
KR20010032304A (ko) 2001-04-16
AR016423A1 (es) 2001-07-04
EA200000433A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
BR9814698A (pt) Combinação de um inibidor da aldose-redutase com um inibidor do glicogênio-fosforilase
BR0014384A (pt) Compostos para o tratamento da isquémia
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
BR0317822A (pt) Composição fluoroquìmica
DE69910045D1 (de) Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
WO2004088233A3 (en) Thermal surgical procedures and compositions
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
ATE485049T1 (de) Physiologisch aktive zusammensetzung gegen diabetes
BR0011291A (pt) Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz
EA200000165A1 (ru) Разветвленные алкоксизамещенные-2-аминопиридины в качестве ингибиторов nos
CU23432B6 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
NO20000045D0 (no) Farmasoeytiske blandinger omfattende en aldosereduktase- inhibitor og en ace-inhibitor
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
ATE444083T1 (de) Selektives targeting von apoptotischen zellen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.